Friday, February 21, 2014

MRL's Dr. Roger Perlmutter To Present To Investors Monday Morning, In Manhattan: Citi 2014 HC Confab

I will have a second post up shortly, on this early snowy Friday morning, outlining at least one of the second dip collaborations Dr. Perlmutter may highlight, come Monday in Manhattan. He is likely also to discuss the FDA acceptance (regular review) of an BLA (the biologics equivalent of an NDA) for the next gen HPV vaccine candidate, called V-503, at MRL.

I don't imagine that he'll discuss Merck's nascent Zen approach to IP problems, in India -- as that is not technically within his portfolio of responsibilities at Whitehouse Station. But one can hope. Here are the details; I'll listen in to the web-cast.

. . . .Dr. Roger M. Perlmutter, president, Merck Research Laboratories, is scheduled to speak at the Citi 2014 Healthcare Conference in New York City on February 24, 2014 at 8:50 a.m. EST. Investors, analysts, members of the media and the general public are invited to join a live webcast of the presentation. . . .

In general, I expect nothing Earth-shattering. And I do not expect a Consumer Health announcement of any kind -- or size, just yet. Not $6 billion; and certainly not $12 billion -- not yet. In the meantime, be excellent to one another.

No comments: